Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. has secured a new C$12 million convertible debt facility aimed at strengthening its capital structure and ensuring operational funding until Q2 2025. This move comes as the company also updates on the settlement of its existing debt with Silicon Valley Bank, expecting to finalize payments by Q3 2024. The pharmaceutical company continues to progress with its clinical programs, focusing on treatments for eosinophilic esophagitis and osteoarthritis.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
